iiinova — where your digital self keeps evolving

Lingling Tian @linglingtian.bsky.social · 21/08/2026

🧬 New publication International experts share key recommendations on biomarker testing in advanced/metastatic HR+/HER2- #breastcancer, offering practical guidance to support precision oncology and treatment decision-making. 📖 Read here: buff.ly/qkAjgAi #Oncology #Biomarkers #PrecisionMedicine

011

Lingling Tian @linglingtian.bsky.social · 22/07/2026

🧬 New research in esophagogastric cancer highlights the prognostic value of type V collagen biomarkers. Serum C-terminal pro-peptide levels may help identify desmoplasia subtypes with clinical relevance. Read more 👇 buff.ly/ov287mf #Oncology #CancerResearch #Biomarkers #PrecisionMedicine

011

Lingling Tian @linglingtian.bsky.social · 18/07/2026

🚨 Call for Papers! Submit to our special collection on bladder-sparing strategies in urothelial carcinoma 🧪 Novel therapies & combinations 📈 Emerging clinical insights 👉 Learn more & submit: buff.ly/x5jNw3U #CallForPapers #Oncology #CancerResearch

031

Lingling Tian @linglingtian.bsky.social · 15/07/2026

🆕 Rare epithelial gastric cancers remain an underexplored clinical challenge. This review synthesizes current treatment strategies & emerging insights to guide practice and future research. 🔗 Read the article buff.ly/V8qSVm8 #Oncology #GastricCancer #CancerResearch #ClinicalInsights

021

Lingling Tian @linglingtian.bsky.social · 11/07/2026

🚨 Call for Papers! Submit to our special collection: Clinical Trials Driving Innovation in Oncology 🧬 Share your latest research in Therapeutic Advances in Medical Oncology 📩 Submit here: buff.ly/bioqZyF #CallForPapers #Oncology #ClinicalTrials #CancerResearch

031

Lingling Tian @linglingtian.bsky.social · 08/07/2026

🧬 What’s next for EBV-positive #gastriccancer? This review highlights key molecular mechanisms and evolving therapeutic strategies, offering a comprehensive look at opportunities for more targeted, personalized care. 📖 Read:https://buff.ly/AAZpU90 #EBV #PrecisionOncology #CancerResearch

011

Lingling Tian @linglingtian.bsky.social · 04/07/2026

🧬 How is genomics reshaping our understanding of #ovariancancer? This review highlights the growing role of precision medicine in improving diagnosis and treatment pathways - offering insights into the future of personalized oncology care.🔗 Dive in: buff.ly/iqYxZYe #PrecisionOncology #CancerResearch

021

Lingling Tian @linglingtian.bsky.social · 01/07/2026

📣 Call for Papers - Special Collection: TME in GI Cancers 🔬 Biomarkers & clinical impact 🧬 Translational & clinical studies welcome 🗓 Deadline: 15 Mar 2027 👉 buff.ly/dpUqDMk #CallForPapers #Oncology #GICancers #CancerResearch

011

Lingling Tian @linglingtian.bsky.social · 27/06/2026

🧬 How should we sequence antibody–drug conjugates in metastatic breast cancer? This review maps the current landscape and evolving strategies for optimizing ADC use in clinical practice. 🔗 Read now: buff.ly/9SJkVZ1 #BreastCancer #Oncology #ADCs #CancerResearch

021

Lingling Tian @linglingtian.bsky.social · 25/06/2026

🧠 How can we better prevent & manage cytokine release syndrome (CRS) in solid tumours? This review explores mechanism-based therapeutic strategies to improve patient outcomes in oncology. 📖 Read now: buff.ly/ZDar0oT #Oncology #CancerResearch #Immunotherapy #CRS #MedEd

011

Lingling Tian @linglingtian.bsky.social · 24/06/2026

🧬 Can tumor-agnostic strategies unlock new options for SMARCA4-deficient malignancies? This reivew explores emerging therapeutic approaches across cancer types. 🔗 Read now: buff.ly/uc7XNaA #Oncology #PrecisionMedicine #TumorAgnostic #CancerResearch

011

Lingling Tian @linglingtian.bsky.social · 20/06/2026

🧬 What role does the tumor microenvironment play in lung adenocarcinoma metastases? This review explores key alterations & biomarkers—and their impact on treatment response and prognosis. 🔗 Read now: buff.ly/AzpRbgj #LungCancer #Oncology #TumorMicroenvironment #Biomarkers

011

Lingling Tian @linglingtian.bsky.social · 17/06/2026

🧬 Neoadjuvant trastuzumab + pertuzumab + carboplatin-based therapy shows promising results in HER2+ breast cancer—paired with integrated genomic & transcriptomic biomarker analysis. 🔗 Read now: buff.ly/WZ97gu5 #BreastCancer #HER2 #Oncology #Biomarkers

021

Lingling Tian @linglingtian.bsky.social · 13/06/2026

📊 Antibody–drug conjugates outperform chemotherapy in EGFR-TKI-resistant NSCLC, according to this Bayesian network meta-analysis. What does this mean for post-TKI treatment strategies? 🔗 Read now: buff.ly/mBdISSD #Oncology #NSCLC #LungCancer #ADCs #CancerResearch

031

Lingling Tian @linglingtian.bsky.social · 10/06/2026

🧬 New review: What are the current standards, and what’s next, for platinum-refractory male germ cell cancers? This article explores evolving strategies and future directions in a challenging treatment landscape. 🔗 Read more: buff.ly/QqtRKue #Oncology #GermCellTumors #CancerResearch #Urology

011

Lingling Tian @linglingtian.bsky.social · 06/06/2026

📊 New real-world evidence:How do apalutamide and enzalutamide compare for PSA response in metastatic castration-sensitive prostate cancer? This study provides important comparative insights to inform treatment decisions. 🔗 Read now: buff.ly/CsFU3XV #ProstateCancer #Oncology #RealWorldEvidence #mCSPC

031

Lingling Tian @linglingtian.bsky.social · 03/06/2026

🧪 New study protocol published! TROPION-Lung14 (phase III) evaluates osimertinib + datopotamab deruxtecan vs osimertinib alone in 1L EGFR-mutated advanced NSCLC. Could combination therapy reshape first-line treatment? 🔗 Read more: buff.ly/pp3eAk2 #Oncology #LungCancer #NSCLC #ClinicalTrials #EGFR

141

Lingling Tian @linglingtian.bsky.social · 30/05/2026

📣 Call for Papers: Advances in Targeted Therapeutics for Pancreatic Cancer: Redefining Precision Oncology in the KRAS Era ✅ Open now | 📅 Deadline Mar 1, 2027 KRAS targeting, resistance, combinations, beyond KRAS & advanced models. 🔗 buff.ly/eMwzb2N #PancreaticCancer #KRAS #Oncology #CallForPapers

021

Lingling Tian @linglingtian.bsky.social · 27/05/2026

🆕 New - Does timing matter in radiotherapy? This study shows that time‑of‑day radiotherapy influences radiation pneumonitis risk, but not survival, in #lungcancer patients with #ILD 🔗 buff.ly/vvUviVC #Radiotherapy #CancerToxicity #Oncology

031

Lingling Tian @linglingtian.bsky.social · 23/05/2026

🧠📣 New Special Collection in Ther Adv Med Oncol: #ADCs in Gynecologic Cancers. We invite clinically focused work on ADC targets, sequencing, toxicity, and combinations in ovarian, endometrial, and cervical cancers. 🗓️ Deadline: 26 Feb 2027 buff.ly/30K8r13 #GyneOnc #CancerTrials

011

Lingling Tian @linglingtian.bsky.social · 20/05/2026

Using spatial profiling, scRNA‑seq, and transcriptomic meta‑analysis, this study links S100A4⁺ antigen‑presenting CAFs with immune‑rich niches and complete resection outcomes in relapsed ovarian cancer. buff.ly/hL0LhWe #OvarianCancer #TumorMicroenvironment #CAFs

041

Lingling Tian @linglingtian.bsky.social · 16/05/2026

Precision approaches have reshaped AML care, yet relapse and resistance remain major challenges. This Collection seeks clinically grounded and translational work addressing MRD, molecular risk, immune strategies, and treatment sequencing across #AML. Deadline: 19 Feb 2027 buff.ly/xsqkygl

011

Lingling Tian @linglingtian.bsky.social · 13/05/2026

In resected #AcralMelanoma, this multicenter retrospective study found adjuvant anti‑PD‑1 therapy achieved RFS comparable to high‑dose interferon, with substantially fewer grade 3–4 toxicities. KIT‑mutant disease showed a signal of greater benefit. Ther Adv Med Oncol buff.ly/QukRAI9 #Immunotherapy

021

Lingling Tian @linglingtian.bsky.social · 09/05/2026

After the strong response to Volume 1, this second volume of our #ADC Special Collection reflects how rapidly these agents are redefining breast cancer treatment-from sequencing questions to biomarkers and toxicity management. Submissions open until 29 Jan 2027 buff.ly/RS4HyAZ #BreastCancerResearch

021

Lingling Tian @linglingtian.bsky.social · 06/05/2026

Later-line #pancreaticcancer care lacks validated prognostic tools. The NAPOLEON‑2 study explores how prior treatment duration, line of therapy, and inflammation (CAR) relate to PFS with nanoliposomal irinotecan + 5‑FU/LV - proposing a clinically grounded nomogram. buff.ly/0XFh0X5 #MedicalOncology

011

Lingling Tian @linglingtian.bsky.social · 02/05/2026

Immunotherapy for #TCellMalignancies raises unique challenges-from antigen overlap to CAR‑T fratricide. This Special Collection brings together translational and early clinical insights addressing these barriers. Submissions open until 29 Jan 2027 Ther Adv Med Oncol buff.ly/y2kbSVy

041

Lingling Tian @linglingtian.bsky.social · 29/04/2026

Can intensified strategies improve outcomes in advanced #biliarycancer? This multicentre #realworld study reports outcomes of a highly selected subset treated with chemo‑immunotherapy followed by multimodality local approaches in the #immunotherapy era. buff.ly/Ygnhnjn Ther Adv Med Oncol #Oncology

011

Lingling Tian @linglingtian.bsky.social · 25/04/2026

Biomarkers are now shaping #LungCancer care across the entire disease continuum. This Collection in Ther Adv Med Oncol examines how biomarker‑driven strategies are being translated into clinical practice. Submit by January 29, 2027 buff.ly/RrkerAu

011

Lingling Tian @linglingtian.bsky.social · 21/04/2026

Real‑world data can complement trial evidence. In this retrospective Chinese cohort, sacituzumab govitecan showed activity in metastatic #BreastCancer, with exploratory analyses suggesting potential associations with prior immunotherapy and PIK3CA status. buff.ly/6v5lzLX #TranslationalResearch #ADC

011

Lingling Tian @linglingtian.bsky.social · 18/04/2026

The therapeutic landscape of HR+HER2‑ advanced #BreastCancer has expanded rapidly, yet heterogeneity, resistance, and treatment sequencing remain unresolved challenges. This Collection in Ther Adv Med Oncol focuses on research shaping a more individualized therapeutic roadmap. buff.ly/Da8ENXI

011

Lingling Tian @linglingtian.bsky.social · 15/04/2026

#EndometrialCancer is increasingly understood as a group of molecularly distinct diseases. This review in Ther Adv Med Oncol examines hereditary cancer syndromes predisposing to EC and their implications for prognosis, biology, and emerging therapeutic approaches. buff.ly/9UGqCj9 #CancerGenetics

011

Lingling Tian @linglingtian.bsky.social · 11/04/2026

#Glioblastoma care depends on high‑quality, integrated clinical decision‑making across the full treatment pathway. Ther Adv Med Oncol invites submissions to a special collection on clinically actionable advances in glioblastoma care. Submission deadline: 11 Dec 2026 buff.ly/8jRyYqj #NeuroOncology

011

Lingling Tian @linglingtian.bsky.social · 08/04/2026

#ADCs have moved from concept to clinical reality in #breastcancer -but important questions remain. This Ther Adv Med Oncol special collection, guest edited by Paolo Tarantino, MD, and Ilana Schlam, MD, explores efficacy, biomarkers, sequencing, and toxicity. buff.ly/pZycpW5 #BreastCancer

011

Lingling Tian @linglingtian.bsky.social · 04/04/2026

Patient selection in #BreastCancer is evolving rapidly, with advances in AI, ctDNA‑based MRD detection, and multi‑omic profiling. Ther Adv Med Oncol invites submissions to a special collection on modern approaches to patient selection. Submission deadline: 11 Dec 2026 buff.ly/t6TEH5G

011

Lingling Tian @linglingtian.bsky.social · 01/04/2026

Antibody-drug conjugates are re-emerging as a promising strategy in advanced prostate cancer. This review examines key targets, clinical trial data, and how next-generation ADCs may overcome earlier limitations. Ther Adv Med Oncol buff.ly/nFWU1s6 #ProstateCancer #ADCs #Oncology

011

Lingling Tian @linglingtian.bsky.social · 28/03/2026

We invite submissions to the Special Collection Advances in Biomarkers for Genitourinary Cancers in Ther Adv Med Onc. We welcome studies on diagnostic, prognostic, predictive and molecular biomarkers across GU malignancies. buff.ly/sQgaDWS #GUcancer #Oncology #ProstateCancer #BladderCancer

000

Lingling Tian @linglingtian.bsky.social · 25/03/2026

A large pan‑cancer analysis of 1667 metastatic tumors shows KRAS aberrations in 28.1%, dominated by G12D, G12V and G13D. Mutation type influenced survival, and KRAS amplification varied across tumor types. buff.ly/ClRCkHG #KRAS #Oncology #NGS #PrecisionMedicine #TherAdvMedOnc

011

Lingling Tian @linglingtian.bsky.social · 21/03/2026

We welcomes submissions to the Ther Adv Med Onc Special Collection on Combined Immunotherapy Strategies for Advanced Hepatocellular Carcinoma. We invite work on ICI combinations, biomarkers, and translational insights. buff.ly/e8XA6kU #HCC #Immunotherapy #Oncology

021

Lingling Tian @linglingtian.bsky.social · 18/03/2026

A TAMO study evaluates the #costeffectiveness of #belzutifan vs everolimus for previously treated advanced ccRCC. At current pricing, belzutifan is unlikely to be cost‑effective in the US or China, highlighting the role of pricing in access. buff.ly/CxCmOzE #Oncology #RCC #HealthEconomics

011

Lingling Tian @linglingtian.bsky.social · 14/03/2026

Call for Papers: This Special Collection examines clinical and translational developments in high‑risk HER2+ early breast cancer, including response‑adapted strategies, ADCs, and biomarker‑guided approaches. buff.ly/3jv7zmw #BreastCancer #Oncology #HER2 #MedOnc #ClinicalTrials

011

Lingling Tian @linglingtian.bsky.social · 11/03/2026

Ther Adv Med Oncol: Real‑world comparison of mFOLFOX‑6 vs mDCF in metastatic gastric/GEJ cancer (n=493, 25 hospitals): • PFS: 7 vs 6 mo • OS: 11 vs 12 mo • Similar ORR • Lower grade 3–4 neutropenia/anemia with mFOLFOX‑6 Read: 【🔗https://buff.ly/kUKcGAz 】 #GastricCancer #GIOnc #Chemotherapy

011

Lingling Tian @linglingtian.bsky.social · 07/03/2026

Ther Adv Med Oncol: Real‑world pyrotinib beyond progression vs rechallenge in HER2+ mBC (incl. brain mets): PFS2 ~7.2 vs 6.3 mo (NS); OS 31.6 vs 21.0 mo (trend). CNS subgroup also benefited. Read: 【🔗https://buff.ly/xsK4lFw 】 #BreastCancer #HER2 #BrainMets #Oncology

032

Lingling Tian @linglingtian.bsky.social · 04/03/2026

A multicenter randomized trial shows PLD+carboplatin delivers non‑inferior PFS and significantly lower neurotoxicity and alopecia vs paclitaxel+carboplatin in 1L epithelial ovarian cancer. A promising taxane‑sparing option. 🔗 buff.ly/umFC4iX #OvarianCancer #GynOnc #Chemotherapy #PLD #Paclitaxel

011

Lingling Tian @linglingtian.bsky.social · 28/02/2026

Analysis of 346 BCBM cases from the GEICAM RegistEM registry reveals faster CNS progression and poorer survival in TNBC and HER2+ subtypes, with major differences between de novo vs subsequent brain metastases. 🔗 buff.ly/74yHwuH #BreastCancer #BrainMets #HER2 #TNBC #RealWorldEvidence

012

Lingling Tian @linglingtian.bsky.social · 25/02/2026

New review - The treatment landscape for advanced gastric/GEJ adenocarcinoma is rapidly evolving. Upfront ICIs, targeted agents, and biomarker‑guided strategies are reshaping first‑line, maintenance, and sequential therapy. 🔗 buff.ly/22B0Oz0 #GastricCancer #GEJ #Immunotherapy #TargetedTherapy

021

Lingling Tian @linglingtian.bsky.social · 18/02/2026

A new multicenter Chinese study in Ther Adv Med Onc evaluated PARPi in metastatic #breastcancer with HRR gene pathogenic variants. mPFS reached 6.0 months, with consistent benefit across BRCA1/2, PALB2 and other HRR mutations. 🔗 buff.ly/x4JnB05 #MBC #PARP #HRR

111

Lingling Tian @linglingtian.bsky.social · 16/02/2026

Happy Lunar New Year’s Eve! 🎇 Welcoming the Year of the Horse with gratitude for a year working alongside the global oncology community through Therapeutic Advances in Medical Oncology and Sage Oncology journals. Wishing everyone health, energy, and new breakthroughs in the year ahead. 🐎✨ 马年大吉！

011

Lingling Tian @linglingtian.bsky.social · 13/02/2026

New review highlights how PSMA‑targeted radioligand therapy, including 177Lu‑PSMA‑617 and emerging isotopes like 225Ac/161Tb, is reshaping advanced prostate cancer care. Combination strategies and precision dosimetry point to a rapidly evolving future. 🔗 buff.ly/WKhPij0 #ProstateCancer #RLT #PSMA

011

Lingling Tian @linglingtian.bsky.social · 10/02/2026

A new review examines how gut microbiota influence response and toxicity to neoadjuvant chemoradiotherapy in LARC. Beneficial species (e.g., Akkermansia, Alistipes) may enhance treatment effect, while pathogens like F. nucleatum may drive resistance. 🔗 buff.ly/PefDIka

111

Lingling Tian @linglingtian.bsky.social · 07/02/2026

Early NSCLC is entering a new era. Broad NGS profiling now identifies actionable mutations that guide adjuvant EGFR/ALK‑targeted therapy, influence immunotherapy decisions, and support ctDNA‑based MRD monitoring. 🔗 buff.ly/FKnT16B #NSCLC #LungCancer #NGS #ctDNA #MRD #PrecisionOncology

011